Shots:

• The companies collaborated to evaluate the safety, tolerability, and efficacy of Mirati's adagrasib (KRASG12C inhibitor) + Verastem's VS-6766 (RAF/MEK inhibitor) in the P-I/II trial for KRASG12C-mutant NSCLC. The trial is based on the results from the preclinical studies
• The primary objective is to determine the maximum tolerated dose and RP2D for the combination of adagrasib and VS-6766
• Adagrasib is being evaluated in multiple clinical trials in combination with other anti-cancer therapies in patients with advanced solid tumors & showed a response in monothx. therapy for NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors with KRASG12C mutations

Click here to­ read full press release

Ref: Mirati | Image: Mirati